As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate pelacarsen to a Phase III test of Eli Lilly’s next-gen Alzheimer's drug—are poised ...

Upon completion of both tranches, PharmaDrug will hold a 40% interest in Canurta, and Canurta limited partners will hold approximately 44% of PharmaDrug's issued and outstanding shares on a pro forma ...

Animal Health, a value-added distributor and solutions provider, and Vetramil USA Inc., have entered into a distribution and strategy ...

The United States Postal Service has reached a pivotal moment. Challenged by technological disruptions and constrained by outdated regulations, it is in the midst of a major restructuring plan to ...

BLANTYRE-(MaraviPost)-The High Court of Malawi’s Civil Division has consolidated two cases involving former Electricity Supply Corporation of Malawi (Escom) executives Kamkwamba Kumwenda and Chrispin ...

Ali Larter’s perfectly undone, goddess-level waves at the 2026 Critics Choice Awards have all the hallmarks of a major hair moment: shine, bounce and soft, touchable movement. T ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

Much of the focus on generative artificial intelligence (GenAI) has been on training data ingestion—the moment when AI ...

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...

Slomp Filho, M. (2026) Copyright in Generative Artificial Intelligence. Beijing Law Review, 17, 1-10. doi: ...